Hepatitis B is an infection of the liver attributable to the hepatitis B virus, which may present as a short severe acute illness or as a persistent long-term infection [1]. It is one of several viral hepatitis strains that can lead to chronic liver disease and is distinguished from other types by its specific transmission routes and prevention needs [2].
Disease overview
Hepatitis B is a liver infection caused by the hepatitis B virus that may follow an acute or chronic course and constitutes a major global health burden [1]. Chronic infection carries a high risk of death from cirrhosis and liver cancer [1]. Safe and effective vaccination begun shortly after birth provides near-complete protection [1].
Read the full clinical and epidemiological profile 6
The infection can be acute and short-lived or become chronic over the long term [1]. Chronic hepatitis B places affected persons at high risk of death from cirrhosis and liver cancer [1]. Clinical findings alone cannot distinguish hepatitis B from other viral hepatitides, requiring laboratory confirmation [1].
Hepatitis B is a major global health problem with the highest chronic infection burden in the WHO Western Pacific and African Regions, where an estimated 102 million and 64 million people are chronically infected, respectively [1]. In 2024 the global prevalence of chronic HBV among children under five years was about 0.6% [1]. The African Region, at 1.4% childhood prevalence, remains far from the 2030 elimination target of 0.1%, whereas the European and another WHO region have already surpassed it [1].
The virus spreads through contact with infected body fluids such as blood, vaginal fluids, semen, and saliva when open cuts or sores are present, and from mother to infant [1]. In highly endemic settings the predominant routes are perinatal transmission and horizontal person-to-person spread during early childhood [1]. Additional routes include needlestick injury, tattooing, piercing, and sharing or reusing contaminated needles [1].
A safe and effective hepatitis B vaccine is usually given soon after birth with booster doses a few weeks later and affords nearly 100% protection [1]. Universal childhood vaccination and timely birth-dose administration are essential, particularly in endemic regions with inadequate coverage [1]. Broader elimination strategy also relies on scale-up of vaccination and improved access to prevention and public education to reduce transmission [2].
- 1 World Health Organization. Hepatitis B [Internet]. cited 23 Oct 2026. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
- 2 World Health Organization. Hepatitis [Internet]. cited 1 Sept 2026. Available from: https://www.who.int/health-topics/hepatitis
- 3 Ali FS et al. AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals. Gastroenterology. 2025 Feb. PMID: 39863345. doi: 10.1053/j.gastro.2024.11.008. PubMed: https://pubmed.ncbi.nlm.nih.gov/39863345/
- B16-B18
- 1E50.1-1E51.0
Loading current data…
Country surveillance trends
Choose a country, source, and measure. Each line retains its published reporting period and definition.
Coverage
Reporting countries and regions
The map shows reporting coverage. Select a measure or open a shaded location to inspect its data.
Loading current data…
Surveillance pattern
Year × month seasonality by country
Review one country’s published monthly values by year. Empty cells indicate values the source did not publish.
Research Radar
Recent related research
KẾT QUẢ NỘI KIỂM BẰNG THANG ĐO SIX SIGMA TRONG KIỂM SOÁT CHẤT LƯỢNG XÉT NGHIỆM SÀNG LỌC HBV, HCV, HIV BẰNG KỸ THUẬT ĐIỆN HOÁ PHÁT QUANG TẠI VIỆN HUYẾT HỌC - TRUYỀN MÁU TRUNG ƯƠNG
Tạp chí Y học Việt Nam
Hepatic Steatosis in People With Chronic Hepatitis B in Africa: Prevalence, Correlates, and Clinical Significance.
Journal of viral hepatitis
Awareness regarding the epidemiology, prevention, treatment, and consequences of viral hepatitis among a predominantly young adult population in the Podillia region (Ukraine): a cross-sectional study
Preventive Medicine Reports
A Randomized, Double-Blind, Placebo-Controlled Study of the PD-1 Inhibitor Cetrelimab in Chronic Hepatitis B.
Journal of viral hepatitis
Dysregulated transcription in core- and pol-specific CD8 T cells can be targeted by HDAC inhibition to improve T-cell function in chronic hepatitis B
Journal of Hepatology
Showing 5 of 156 related publications.
Literature links are provided for discovery and do not alter or validate the surveillance series above.
Loading official alerts…
Downloads and methods
Choose a time range and download CSV, JSON or XLSX files.

